Researchers have identified a hidden allosteric 'on switch' in the ICL2 enzyme of Mycobacterium tuberculosis, offering a new pathway to target drug-resistant strains. Using advanced imaging at the ...

About GT-02287 Gain Therapeutics’ lead drug candidate, GT-02287, is in clinical development for the treatment of Parkinson’s disease (PD) with or without a GBA1 mutation. The orally administered, ...

According to a recently published research paper by a team of scientists, a groundbreaking approach has been developed to create artificial allosteric sites (where by binding an effector molecule, ...

Sir2, an enzyme belonging to sirtuins, has been effectively involved in the deacetylation of proteins. A tandem allosteric effect of reactant and product is responsible for the efficient deacetylation ...

In this Innovation Spotlight, Gene Mack, the chief executive officer of Gain Therapeutics, discusses the company’s Magellan™ platform, which uss machine learning and structural modeling to identify ...

Gain Therapeutics, Inc. (NASDAQ: GANX) shares -made miniscule gains Friday. The Bethesda, Md.-based firm, a clinical-stage biotechnology company leading the discovery and development of the next ...

Researchers have made a major breakthrough earlier this year in the field of evolutionary conservation of molecular dynamics in enzymes. Their work points to potential applications in health, ...

Sir2, an enzyme belonging to sirtuins, has been effectively involved in the deacetylation of proteins. A tandem allosteric effect of reactant and product is responsible for the efficient deacetylation ...

Researchers at the Centre for Genomic Regulation and the Wellcome Sanger Institute have comprehensively identified the allosteric control sites found in the protein KRAS, which is one of the most ...

Researchers at the University of Melbourne have identified a hidden allosteric mechanism that activates ICL2, a key enzyme in ...